When 777 patients with decompensated liver cirrhosis in the United Kingdom were randomized to receive an albumin infusion to target a serum albumin of ≥30 g/L versus standard of care, albumin did not provide additional benefit in terms of lower rates of renal dysfunction, infection, or death between days 3 and 15 after the initiation of treatment. This evidence concerns the gene ALB and cirrhosis of liver.